About ImmunoVec
ImmunoVec is a private company based in Los Angeles, California. It has reported $17,004,780 raised in two offerings on Form D since March 2022. Its chief executive is Ryan Wong.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jun 29, 2026 | Jul 14, 2026 | $12,705,822of $14.9M target | 10 | $1.2M | Equity, Securities on exercise, Preferred Stock and Common Stock issuable upon conversion thereof. Total Offering Amount and Total Amount Sold include conversion of the previously issued convertible securities.Rule 506(b) | Form D ↗ |
| Nov 5, 2021 | Mar 1, 2022 | $4,298,958fully sold | 25 | $171K | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $17,004,780 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on ImmunoVec's Form D filed Jul 14, 2026.
DL
Douglass Lorenzen
Executive officer, director and promoter
RW
CL
Chris Lucas
Director
WW
William Woodward
Chairman, Co-founder
Earlier filings also listed Dillon Woodward (director, last listed Mar 2022).